Multiplex platform technology and bioinformatics are essential for development of biomarkers in atopic dermatitis

Multiplex platform technology and bioinformatics are essential for development of biomarkers in atopic dermatitis

[...]we recently conducted a pilot study in which we demonstrated that a multivariate signature, consisting of serum TARC, PARC/CCL18, IL-22, and sIL-2R levels, showed a correlation coefficient of 0.86 to disease severity.11 We strongly believe that state-of-the-art multiplex platform technology and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2017-03, Vol.139 (3), p.1065-1065
Hauptverfasser: Thijs, Judith L., MD, Herath, Athula, PhD, de Bruin-Weller, Marjolein S., MD, PhD, Hijnen, DirkJan, MD, PhD
Format: Artikel
Sprache:eng
Schlagworte:
Allergies
Allergy and Immunology
Bioinformatics
Biomarkers
Blood Proteins
Chemokines
Computational Biology
Dermatitis
Dermatitis, Atopic
Eczema
Humans
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[...]we recently conducted a pilot study in which we demonstrated that a multivariate signature, consisting of serum TARC, PARC/CCL18, IL-22, and sIL-2R levels, showed a correlation coefficient of 0.86 to disease severity.11 We strongly believe that state-of-the-art multiplex platform technology and bioinformatics can help in developing reliable and objective prediction tools to measure therapeutic effects in AD from serum.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2016.08.023